caa a22 4500 465803490 CHVBK 20180323112058.0 cr unu---uuuuu 170327e19900101xx s 000 0 eng 10.1007/BF03348567 doi (NATIONALLICENCE)springer-10.1007/BF03348567 Effect of hCG or hCG + treatments in young thalassemic patients with hypogonadotropic hypogonadism [Elektronische Daten] [R. Balducci, Vincenzo Toscano, G. Finocchi, G. Municchi, A. Mangiantini, B. Boscherini] Hypogonadotropic hypogonadism (HH) is common (40%) in beta-thalassemic patients. Taking into consideration that in HH non-thalassemic patients we obtained good results in pubertal development using hCG treatment (1500 IU every 6 days), 10 HH thalassemic subjects (14 5/12 -17 yr, all with bone age greater than 13 6/12) were treated with the same regimen. In 5 of these patients purified FSH (75 IU every 3 days) was added to hCG in order to evaluate the FSH effect on testosterone (T) response (Group 1 was given hCG alone, Group 2 hCG + FSH: Profasi HP and Metrodin Serono). To evaluate the kinetics of testosterone response, plasma level of T was determined basally and 1, 2, 4 and 6 days after hCG injection. This dynamic study and a clinical examination were carried out at the beginning of treatment and at the 4th and 12th month after. Results obtained in the first group confirmed our previous data from non-thalassemic HH patients: in fact, after 12 months of therapy a stage G2-G3 was reached. In the second group, however, testis size and testosterone secretion were significantly higher than in the first group. At the 4th month, in Group 1 and in Group 2 testis size and the area under the T response curve were 3.18 ± 0.18ml and 13,364 ± 1047 ng/dl vs 4.62 ± 0.25 ml (p < 0.02) and 18,045 ±1110 ng/dl (p < 0.016), respectively. At the 12th month testis size and area under T response curve were increased to 6.12 ± 0.25 ml and 24,017 + 1176 ng/dl in Group 1 and 8.12 ± 0.6 ml (p < 0.01) and 33,924 ± 2181 ng/dl (p < 0.01) in Group 2. After 12 months, a significant comparable increase in growth velocity, without bone age acceleration, was observed in both groups. Our results demonstrate that hCG or hCG + FSH treatments are able to induce a satisfactory sexual development in thalassemic HH patients; moreover FSH in addition to hCG seems to improve not only testis size as expected, but also testosterone production. Italian Society of Endocrinology (SIE), 1990 Hypogonadotropic hypogonadism nationallicence thalassemia nationallicence hCG nationallicence FSH nationallicence Balducci R. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut Toscano Vincenzo V Clinica Medica, Università di Roma "La Sapienza”, 00100, Rome, Italy aut Finocchi G. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut Municchi G. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut Mangiantini A. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut Boscherini B. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut Journal of Endocrinological Investigation Springer International Publishing 13/1(1990-01-01), 1-7 0391-4097 13:1<1 1990 13 40618 https://doi.org/10.1007/BF03348567 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF03348567 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Balducci R. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 700 1- Toscano Vincenzo V Clinica Medica, Università di Roma "La Sapienza”, 00100, Rome, Italy aut NATIONALLICENCE 700 1- Finocchi G. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 700 1- Municchi G. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 700 1- Mangiantini A. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 700 1- Boscherini B. Clinica Pediatrica 2a Università di Roma "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 773 0- Journal of Endocrinological Investigation Springer International Publishing 13/1(1990-01-01), 1-7 0391-4097 13:1<1 1990 13 40618 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer